닫기
18.97.9.174
18.97.9.174
close menu
Accredited
종 설 : 궤양성대장염에서 Golimumab 치료
REVIEW : Golimumab Therapy in Ulcerative Colitis
문원 ( Won Moon )
UCI I410-ECN-0102-2016-510-000796278

Ulcerative colitis is a chronic inflammatory condition of the colon, characterized by diffuse mucosal inflammation and blood-mixed diarrhea. The main treatment has been 5-aminosalicylic acid, steroid, thiopurine, and anti-tumor necrosis factor alpha (TNF-α) antibodies including infliximab, adalimumab, and golimumab. Golimumab, a new anti-TNF-α agent has been recently approved for patients with moderate to severe ulcerative colitis. Its efficacy and safety has been demonstrated in line with infliximab and adalimumab in preclinical and clinical studies. This review will focus on golimumab therapy in ulcerative colitis.

서 론
본 론
결 론
REFERENCES
[자료제공 : 네이버학술정보]
×